



GNI Group Ltd. Ranked 351st on Deloitte Technology Fast 500 Asia Pacific 2018, A Ranking Program of Fastest-Growing Technology Companies

December 10, 2018 - GNI Group Ltd. announced that it ranked 351st on the Deloitte Technology Fast 500 Asia Pacific 2018 on December 7, with revenue growth of 160.50% based on the past three accounting periods.

Technology Fast 500 Asia Pacific, announced annually by Deloitte Touche Tohmatsu Limited (DTTL), is a ranking of the 500 fastest-growing companies in the technology, media, and telecommunications (TMT) industries based on their revenue (sales) growth percentage based on the last three accounting periods.

Please visit: www.deloitte.com/fast500asiapacific

The Deloitte Technology Fast 500 is the pre-eminent technology awards program in Asia Pacific, and now in its 17th year, it includes eight Asia Pacific locations: Australia; China (including Hong Kong); India; Japan; South Korea; New Zealand; Singapore and Taiwan. Combining technological innovation, entrepreneurship and rapid growth, Technology Fast 500 companies are large, small, public and private, and span a variety of industry sectors including hardware, software, telecommunications, Media, life sciences and clean technology. For further information on Asia Pacific Technology Fast 500, please visit: www.deloitte.com/fast500asiapacific

About GNI Group Ltd.

GNI Group Ltd. is a multinational pharmaceutical company listed on the Tokyo Stock Exchange Mothers Market, Code 2160. The Group is headquartered in Tokyo, with primary business units of pharmaceuticals and medical devices with subsidiaries in Hong Kong, Shanghai, Beijing and the United States. For further information about GNI Group Ltd., please visit www.gnipharma.com.

For further inquiries

Email: infojapan@gnipharma.com

This press release contains "forward-looking" statements, including statements related to our group's plans to pursue development of product candidates and the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "continue," "expected to", "will" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause our group's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials and the commercialization of product candidates. Our group does not undertake any obligation to update forward-looking statements.